Contemporary OB/GYN: BD Onclarity™ HPV Assay: What it means for the future of cervical cancer detection

According to pathology expert Mark H. Stoler, MD, HPV primary screening will become the standard cervical cancer screening method in the US – just like in many other places such as Australia, England, and Scandinavia that are 10 to 15 years ahead in the field.

BD Onclarity™ HPV Assay can be used for HPV primary screening as a highly sensitive screening method and is also the only test currently FDA-approved that offers extended genotyping. In this video interview, Dr. Stoler explains how the BD Onclarity™ HPV Assay is paving the way for better cervical cancer screening, by enabling physicians to individually identify other high-risk HPV genotypes such as HPV 31, that are usually masked by the other HPV tests.